A new letter in European Urology by Edoardo Francini responds to the final overall survival results from the EORTC 1333/PEACE-3 trial, which tested enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer, or mCRPC for short - because oncology apparently believes every difficult situation also needs an acronym PubMed, DOI.
That pairing sounds like science fiction already. One drug, enzalutamide, jams androgen receptor signaling - basically cutting off one of prostate cancer's favorite command channels. The other, radium-223, is a radioactive calcium mimic that homes in on bone metastases and delivers a tiny blast of alpha radiation right where tumor cells have set up camp. It is less "chemo carpet bombing" and more "precision orbital strike on the skeleton."
Why this combo got people interested
Metastatic castration-resistant prostate cancer is the version of prostate cancer that keeps growing even after testosterone has been suppressed. That is a nasty trick, and unfortunately a common one. These tumors often spread to bone, where they can cause pain, fractures, and a lot of trouble that goes way beyond what shows up on a scan.
So the logic behind PEACE-3 was pretty compelling. If enzalutamide slows the cancer's growth signals and radium-223 attacks bone metastases directly, maybe together they do better than either strategy alone. Team-up episodes are popular for a reason. The Avengers did not become a franchise by saying, "Actually, one guy with a shield is probably enough."
The hitch is that oncology combinations are not automatically better. Sometimes adding another therapy gives you deeper responses or longer survival. Sometimes it just gives everyone more paperwork and more side effects.
A quick tour of the battlefield
A little background helps here. Enzalutamide is a standard androgen receptor pathway inhibitor used in advanced prostate cancer. It blocks the tumor's ability to use androgen signaling as fuel. Radium-223 dichloride is approved for patients with mCRPC and symptomatic bone metastases without known visceral metastases. It emits alpha particles, which travel only a very short distance, so the treatment can damage nearby cancer cells in bone while limiting wider collateral damage Parker et al., 2013.
But this area has history, and not all of it is happy. A previous trial, ERA 223, tested radium-223 with abiraterone and found increased fracture risk, which set off alarm bells loud enough to wake the whole field Smith et al., 2019. That led to much more attention on bone-protecting agents such as zoledronic acid or denosumab. In other words, before you send radioactive cavalry into the skeleton, you had better reinforce the walls.
What PEACE-3 was trying to answer
The PEACE-3 trial asked a practical question: if patients with mCRPC and bone metastases receive enzalutamide, does adding radium-223 improve outcomes enough to justify the extra complexity and risk?
The final overall survival results matter because survival is the hardest endpoint to sweet-talk. Scans can flirt. Biomarkers can overpromise. Overall survival is the blunt, unsentimental scoreboard.
Francini's piece is a response, not a full trial report, so it likely comments on how to interpret those final results - what they mean clinically, where enthusiasm is warranted, and where caution still belongs. That may sound less flashy than a splashy new drug approval, but these exchanges matter. Cancer medicine advances not just through big trials, but through the arguments afterward, when experts ask, "Fine, but who actually benefits, and at what cost?"
Why this matters outside the conference hall
If this strategy truly improves survival and remains manageable with proper bone protection, it could help patients whose cancer lives mainly in bone - which is a very common and very painful reality in advanced prostate cancer. Better control of bone-dominant disease could mean fewer skeletal complications, less pain, and more time before the cancer pushes people into the next line of therapy.
That is the real-world angle. Not abstract "progress," but more good days. More time walking around the block instead of sitting in an infusion chair wondering why all hospital chairs were designed by villains.
At the same time, combination therapy always raises hard questions. Who should get it early? Does every patient with bone metastases benefit, or only a subset? How much does bone health support change the safety picture? And where does this fit among other options now reshaping prostate cancer care, including PARP inhibitors and radioligand therapies such as lutetium-177 PSMA Sartor et al., 2021, Chi et al., 2019.
The bigger plot twist
The most interesting thing here may be bigger than one trial. Prostate cancer treatment is becoming a layered campaign: hormone blockade, targeted radiation, bone protection, genomic matching, and increasingly personalized sequencing. It is less like throwing one punch and more like coordinating a fleet in orbit while the enemy keeps rewriting its own code. Which, rude.
Recent reviews have emphasized exactly this shift - treatment decisions now depend on disease location, symptoms, prior therapies, molecular features, and the patient's overall condition, not just a one-size-fits-all playbook Mottet et al., 2024, Morgans and Antonarakis, 2023.
So while Francini's response is brief, the topic it touches is huge. It speaks to a central problem in oncology: when you have two clever tools, do they become a better machine together, or just a more expensive Swiss Army knife with one suspiciously sharp hinge?
For patients with metastatic castration-resistant prostate cancer, that answer is never academic. It lives in the clinic, in the scan review, in the fracture risk discussion, and in the hope that the next treatment is not just newer, but actually better.
References
-
Francini E. Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2026. doi:10.1016/j.eururo.2026.05.012
-
Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213-223. doi:10.1056/NEJMoa1213755
-
Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408-419. doi:10.1016/S1470-2045(18)30860-X
-
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322
-
Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. Lancet. 2019;394(10192):131-140. doi:10.1016/S0140-6736(19)31236-1
-
Morgans AK, Antonarakis ES. Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41(9):1724-1736. doi:10.1200/JCO.22.02370
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.